Chinese drugmakers' 2026 overseas licensing deals hit $139 billion, topping last year's record

Chinese drugmakers' overseas licensing deals reached $139 billion in 2026, beating last year's record, Reuters Breakingviews reports. Its commentary says Big Pharma is turning to China's labs for cancer and obesity breakthroughs, while companies such as Hengrui Pharma capture more of the upside from their discoveries.